Eva Kozanli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eva Kozanli has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Eggink
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
6 shared publications - Gesa Carstens
Dutch National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, The Netherlands
4 shared publications - Albert Jan van Hoek
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
3 shared publications Jordy de Bakker
Dutch National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb), Bilthoven, the Netherlands
3 shared publicationsMansoer Elahi
Dutch National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb), Bilthoven, the Netherlands
3 shared publications- Susan van Den Hof
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Elsevier in Public Health
- Vol. 259
Emergence of COVID-19 variant XFG not linked to higher rates of sore throat or altered severity: Evidence from participatory surveillance in the Netherlands
- 13 August 2026
- Published by Elsevier in Public Health
- Vol. 259
Open AccessEmergence of COVID-19 variant XFG not linked to higher rates of sore throat or altered severity: Evidence from participatory surveillance in the Netherlands
- Open Access
- 22 March 2025
- Published by Elsevier in Journal of Infection
- Vol. 90 (5) , 106474
Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands
- 22 March 2025
- Published by Elsevier in Journal of Infection
- Vol. 90 (5) , 106474
Open AccessCo-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands
- 17 January 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 940-945
Shortened SARS-CoV-2 Viral RNA Shedding in Saliva During Early Omicron Compared to Wild-Type Pandemic Phase
This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus–infected and Omicron-infected household cohorts. Preexisting immunity in participants likely shortens the viral RNA shedding duration and lowers viral load peaks. Frequent saliva sampling can be a convenient tool to study viral load dynamics.
- 17 January 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 940-945
Shortened SARS-CoV-2 Viral RNA Shedding in Saliva During Early Omicron Compared to Wild-Type Pandemic Phase
This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus–infected and Omicron-infected household cohorts. Preexisting immunity in participants likely shortens the viral RNA shedding duration and lowers viral load peaks. Frequent saliva sampling can be a convenient tool to study viral load dynamics.
- Open Access
Shortened SARS-CoV-2 shedding in saliva during early Omicron compared to wild-type pandemic phase
This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus-infected and Omicron-infected household cohorts. Pre-existing immunity in participants likely shortens duration of viral shedding and lowers viral load peaks. Dense saliva sampling can be a convenient tool to study viral load dynamics.
Open AccessShortened SARS-CoV-2 shedding in saliva during early Omicron compared to wild-type pandemic phase
This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus-infected and Omicron-infected household cohorts. Pre-existing immunity in participants likely shortens duration of viral shedding and lowers viral load peaks. Dense saliva sampling can be a convenient tool to study viral load dynamics.
- Open Access
Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands
Objectives Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity. Methods We collected both symptom data and nose- and throat samples from symptomatic people during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands, and tested these for 18 respiratory viruses including SARS-CoV-2. We compared reported health status, symptoms and odds of having a mono respiratory viral infection or co-infection with SARS-CoV-2 and another respiratory virus. Results In total 4,655 samples were included with 22% (n=1,017) testing SARS-CoV-2 positive. Of these 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses (15%; n=17) and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 – 0.24; OR: 0.21 CI 95%: 0.17 – 0.26; respectively). Conclusions SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and adenovirus are frequently observed in the general population, but are not associated with more severe disease compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction with rhinovirus and seasonal coronavirus, possibly decreasing risk of co-infection. Highlights Our study showed viral co-infections in 11% of the SARS-CoV-2 positive participants SARS-CoV-2 mono-infections led to more severe symptoms than the common cold mono-infections with seasonal coronavirus or rhinovirus SARS-CoV-2 co-infections with common cold viruses did not lead to worse health status compared to SARS-CoV-2 mono-infections Odds for mono-infection with common cold virus were higher than for co-infection with SARS-CoV-2 and the respective common cold virus
Open AccessCo-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands
Objectives Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity. Methods We collected both symptom data and nose- and throat samples from symptomatic people during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands, and tested these for 18 respiratory viruses including SARS-CoV-2. We compared reported health status, symptoms and odds of having a mono respiratory viral infection or co-infection with SARS-CoV-2 and another respiratory virus. Results In total 4,655 samples were included with 22% (n=1,017) testing SARS-CoV-2 positive. Of these 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses (15%; n=17) and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 – 0.24; OR: 0.21 CI 95%: 0.17 – 0.26; respectively). Conclusions SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and adenovirus are frequently observed in the general population, but are not associated with more severe disease compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction with rhinovirus and seasonal coronavirus, possibly decreasing risk of co-infection. Highlights Our study showed viral co-infections in 11% of the SARS-CoV-2 positive participants SARS-CoV-2 mono-infections led to more severe symptoms than the common cold mono-infections with seasonal coronavirus or rhinovirus SARS-CoV-2 co-infections with common cold viruses did not lead to worse health status compared to SARS-CoV-2 mono-infections Odds for mono-infection with common cold virus were higher than for co-infection with SARS-CoV-2 and the respective common cold virus
- Open Access
Dutch participatory surveillance framework for evaluating evolutionary changes on SARS-CoV-2 affecting Rapid Diagnostic Test sensitivity in 2022 - 2023.
Background Rapid Diagnostic Tests (RDTs) have been pivotal in the diagnostics for SARS-CoV-2 and policies surrounding self-isolation. When self-testing policies are in place a decreased sensitivity of the virus to RDTs can give benefits for viral spread. However, to monitor for reduced sensitivity of RDTs we rely on the collection of SARS-CoV-2 positive samples from RDT negative patients. Infectieradar, a national participatory surveillance that registers influenza-like symptoms is used as a framework to study false-negative RDT results due to emergence of new virus variants. Methods Participants report weekly on RDT use and symptoms linked to Acute Respiratory Illness (ARI). Each week, all RDT positive and a sample of 200 among RDT negative but symptomatic participants were invited to send in nose throat swabs (NTS). SARS-CoV-2 Ct-values are determined using RT-PCR on NTS samples for RDT positive and RDT (false) negative participants and compared. Sequencing is performed on all eligible samples for phylogenetic analysis of the SARS-CoV-2 nucleocapsid protein and the whole genome sequence. NTS samples of participants with discordant RT-PCR and RDT results are also analyzed using RDTs by professionals in the laboratory. Results Between October 2022 and October 2023, our study had 16,893 participants and we collected 1,757 self-test-positive/NTS PCR positive samples and 359 self-test-negative/NTS PCR positive samples (RDT-/PCR+). These participants were asked to take a SARS-CoV-2 RDT upon symptoms. Within SARS-CoV-2 PCR positive participants, we did not find characteristics that differ in SARS-CoV-2 RDT negative versus positive participants. There were no associations with specific changes in the N protein nor did our phylogenetic analysis show clustering of RDT negative samples. Conclusion Evaluating brand-specific RDT performance in Dutch population and false-negative RDT analyses, led to no evidence for SARS-CoV-2 evolution affecting RDT sensitivity. The participatory surveillance program Infectieradar is a powerful tool for our national surveillance on acute respiratory illnesses, as well as for research purposes. Since this framework offered both self-testing and the gold standard of PCR testing results.
Open AccessDutch participatory surveillance framework for evaluating evolutionary changes on SARS-CoV-2 affecting Rapid Diagnostic Test sensitivity in 2022 - 2023.
Background Rapid Diagnostic Tests (RDTs) have been pivotal in the diagnostics for SARS-CoV-2 and policies surrounding self-isolation. When self-testing policies are in place a decreased sensitivity of the virus to RDTs can give benefits for viral spread. However, to monitor for reduced sensitivity of RDTs we rely on the collection of SARS-CoV-2 positive samples from RDT negative patients. Infectieradar, a national participatory surveillance that registers influenza-like symptoms is used as a framework to study false-negative RDT results due to emergence of new virus variants. Methods Participants report weekly on RDT use and symptoms linked to Acute Respiratory Illness (ARI). Each week, all RDT positive and a sample of 200 among RDT negative but symptomatic participants were invited to send in nose throat swabs (NTS). SARS-CoV-2 Ct-values are determined using RT-PCR on NTS samples for RDT positive and RDT (false) negative participants and compared. Sequencing is performed on all eligible samples for phylogenetic analysis of the SARS-CoV-2 nucleocapsid protein and the whole genome sequence. NTS samples of participants with discordant RT-PCR and RDT results are also analyzed using RDTs by professionals in the laboratory. Results Between October 2022 and October 2023, our study had 16,893 participants and we collected 1,757 self-test-positive/NTS PCR positive samples and 359 self-test-negative/NTS PCR positive samples (RDT-/PCR+). These participants were asked to take a SARS-CoV-2 RDT upon symptoms. Within SARS-CoV-2 PCR positive participants, we did not find characteristics that differ in SARS-CoV-2 RDT negative versus positive participants. There were no associations with specific changes in the N protein nor did our phylogenetic analysis show clustering of RDT negative samples. Conclusion Evaluating brand-specific RDT performance in Dutch population and false-negative RDT analyses, led to no evidence for SARS-CoV-2 evolution affecting RDT sensitivity. The participatory surveillance program Infectieradar is a powerful tool for our national surveillance on acute respiratory illnesses, as well as for research purposes. Since this framework offered both self-testing and the gold standard of PCR testing results.